Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Rx Access PR Effort Needs Hiatus, Pfizer Says; Roche Wants To Get Personal

  • News

Executive Summary

Industry should take a hiatus from public relations messages that advocate patient access to drugs, Pfizer VP-Corporate Affairs Robert Mallett said at the Pharmaceutical Leadership Forum Conference in Washington, D.C. Nov. 18

You may also be interested in...



Rx Image Troubles Reflect Flaws In Health Insurance Coverage, Lilly CEO Says

A better health insurance system would help the image of the pharmaceutical industry, Lilly CEO Sidney Taurel declared during a Hudson Institute-sponsored luncheon in Washington, D.C. Nov. 4

Trimeris Expands Fuzeon Distribution; Reimbursement Remains Challenge

Roche and Trimeris are expanding distribution of the HIV therapy Fuzeon into retail channels through StatScript, the companies said during an analyst call Sept. 25

Pfizer Crafting Industry Image Campaign Outside Of PhRMA

Pfizer is discussing an Edelman-developed industry image campaign with the PhRMA membership

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS042890

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By